TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
28/02/2024
Voltar para busca
Dado oficial do USPTO
CRINETICS PHARMACEUTICALS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
48
Atualização mais recente
28/02/2024
Tipo de marca
Mista
Classes Nice
42
Data de depósito
12/04/2018
Data de registro
28/12/2021
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
28/12/2021
Última transação
28/02/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
12/05/2021
Primeiro uso no comércio
12/05/2021
Código do desenho
3
Tipo de titular
03
Localização do titular
San Diego, CA
Examinador
KEELEY, ALISON
Unidade examinadora
M40
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the word "CRINETICS" above the word "PHARMACEUTICALS" with a dot and line spirograph design in the shape of a half circle starting above the letter "I" in "CRINETICS" and wrapping around the first letter "C" in "CRINETICS".
Titulares e representantes
Titulares
Crinetics Pharmaceuticals, Inc.
Representantes
Danny M. Awdeh Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of modulating neuropeptides and G-protein coupled receptors (GPCRs); medical research for use in oncology; medical research in the field of pharmacology for treating endocrine disorders and endocrine-related cancers; pharmaceutical research for the purpose of targeting neuropeptide receptors; pharmaceutical research for treating acromegalyneuroendocrine tumorsCushing's Diseasehyperinsulinismchronic pain; medical research for the treatment or prevention of dermatologicalcardiovascularhematologicalbonerespiratorycentral nervous systemendocrinologicalcirculatorygastroenterologicaldigestivehormonaldiabeticmuscularrheumaticimmune systemocular and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific researchconducting clinical trials for others
Publicações
Histórico de despachos e eventos da marca no USPTO.
48 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
28/02/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
28/02/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
28/02/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
28/02/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
28/12/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
20/11/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
19/11/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
02/11/2021
IUAF
USE AMENDMENT FILED
29/10/2021
EISU
TEAS STATEMENT OF USE RECEIVED
29/10/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/05/2021
EX5G
SOU EXTENSION 5 GRANTED
07/05/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/05/2021
EXT5
SOU EXTENSION 5 FILED
29/04/2021
EEXT
SOU TEAS EXTENSION RECEIVED
29/04/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
30/10/2020
EX4G
SOU EXTENSION 4 GRANTED
28/10/2020
EXT4
SOU EXTENSION 4 FILED
28/10/2020
EEXT
SOU TEAS EXTENSION RECEIVED
28/10/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
28/04/2020
EX3G
SOU EXTENSION 3 GRANTED
24/04/2020
EXT3
SOU EXTENSION 3 FILED
24/04/2020
EEXT
SOU TEAS EXTENSION RECEIVED
24/04/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
23/10/2019
EX2G
SOU EXTENSION 2 GRANTED
21/10/2019
EXT2
SOU EXTENSION 2 FILED
21/10/2019
EEXT
SOU TEAS EXTENSION RECEIVED
21/10/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
19/04/2019
EX1G
SOU EXTENSION 1 GRANTED
17/04/2019
EXT1
SOU EXTENSION 1 FILED
17/04/2019
EEXT
SOU TEAS EXTENSION RECEIVED
17/04/2019
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/04/2019
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
17/04/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
13/11/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/09/2018
PUBO
PUBLISHED FOR OPPOSITION
18/09/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/08/2018
ALIE
ASSIGNED TO LIE
16/08/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/08/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
06/08/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/08/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
06/08/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/08/2018
DOCK
ASSIGNED TO EXAMINER
31/07/2018
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
24/04/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/04/2018
NWAP
NEW APPLICATION ENTERED
16/04/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CRINETICS PHARMACEUTICALS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.